Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature
作者机构：The Second Department of Hepatobiliary SurgeryYantai Yuhuangding HospitalYantai 264000Shandong ProvinceChina
出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)
年 卷 期：2023年第15卷第11期
页 面：2033-2040页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Cholangiocarcinoma Immune-checkpoint-inhibitor Lenvatinib Sintilimab Epigastric metastasis Immunotherapy Case report
摘 要：BACKGROUND Cholangiocarcinoma(CCA)poses a significant clinical challenge due to its low radical resection rate and a propensity for high postoperative recurrence,resulting in a poor *** the combination of targeted therapy and immunotherapy has demonstrated notable efficacy in several solid tumors recently,however,its application in CCA remains underexplored and poorly *** SUMMARY This case report describes a patient diagnosed with stage IV CCA,accompanied by liver and abdominal wall metastases,who underwent palliative ***,the patient received two cycles of treatment combining lenvatinib with sintilimab,which resulted in a reduction in abdominal wall metastasis,while intrahepatic metastasis displayed *** unexpected observation illustrates different responses of intrahepatic and extrahepatic metastases to the same *** Lenvatinib combined with sintilimab shows promise as a potential treatment strategy for advanced *** testing for related driver and/or passenger mutations,as well as an analysis of tumor immune microenvironment analysis,is crucial for optimizing drug combinations and eventually addressing the issue of non-response in specific metastatic sites.
维普期刊数据库